Skip to Main Content

Paper Details

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
PLoS Pathog
10
2022
Author NameAffiliation
Daniel Clark FilesWake Forest University School of Medicine
Frank TackeCharite Universitatsmedizin Berlin
  • 1 - 2

Datasets

Release 1.2